# Lingo: robot model

Canonical ID: `1c39a110-f475-4bbe-a687-83ca13024421`

- **Slug:** abbott-lingo
- **Form factor:** biometric
- **Maturity stage:** commercial
- **Lifecycle:** active
- **Deployments registered:** 0

## Specs

- **notes:** [object Object],[object Object],[object Object],[object Object]
- **specs:** Lingo: over-the-counter continuous glucose monitor (CGM) biosensor for non-diabetic / wellness consumers, built on Abbott's FreeStyle Libre sensor platform. Disposable biosensor worn on the back of the upper arm, up to 14-day wear, glucose-oxidase amperometric assay. FDA 510(k) K233655 decided May 29 2024 (announced Jun 10 2024); Class II integrated CGM (21 CFR 862.1355); indication: adults 18+ NOT on insulin; explicitly NOT for diagnosis of any disease including diabetes. App: real-time glucose graph, 'Lingo Count' daily glucose-spike metric with adaptive targets, food/activity logging, algorithm-driven personalized recommendations, 'Lingo Challenges' behavioral nudges, and 'Lingo Live' (free ~30-min sessions with human Abbott nutritionists). Pricing: entry ~$54 for a 2-week single-biosensor starter plan, recurring biweekly/monthly multi-sensor tiers. Maker: Abbott (NYSE: ABT), Abbott Diabetes Care.
- **formFactor:** biometric (biometric-primary GLUCOSE biosensor / OTC continuous glucose monitor + adaptive insight layer; second glucose example alongside Stelo)

## Deployments

_No deployments registered for this model._

## Supply chain

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model's suppliers._

_Suppliers appear when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is Lingo?

Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.

### Who makes Lingo?

Lingo is made by Abbott, based in Abbott Park, Illinois, USA, founded in 1888.

### Where is Lingo deployed?

No verified deployments of Lingo are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

### What is Lingo's maturity stage?

Lingo is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.


## Sources (3)

1. https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems
2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233655
3. https://www.hellolingo.com/

_API: GET /v1/models/1c39a110-f475-4bbe-a687-83ca13024421 · canonical URL: /models/abbott-lingo_